Aspire BioPharma is trading at $5.95 (-17.87%) amid broader market pressure and a risk-off trading environment, as no company-specific catalysts were reported.
- The decline aligns with a weaker biotech sector and a general retreat across major U.S. stock indexes.
- Rising geopolitical tensions are further contributing to a cautious environment and weighing on equity valuations.